Pediatric transplantation · 2026
Pure Red Cell Aplasia Associated With Recipient B-Cell Mixed Chimerism Successfully Treated With Rituximab.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yokoyama Norifumi, Miyazaki Taichi, Hirate Tomoaki, Ohshiro Ikko, Mori Mari, Kanda Kaori, Shinoda Kunihiro
Аннотация
BACKGROUND: Pure red cell aplasia (PRCA) is a rare but clinically significant complication of allogeneic hematopoietic stem cell transplantation (HSCT), particularly in patients with major ABO incompatibility. Although mixed chimerism is usually evaluated using whole-blood or T-cell-based assays, these approaches may fail to detect lineage-specific immune dysregulation relevant to posttransplant immune complications.
METHODS: We report a pediatric case of late-onset PRCA after reduced-intensity allogeneic HSCT. Clinical course and lineage-specific chimerism analyses were retrospectively reviewed.
RESULTS: Lineage-specific chimerism analysis demonstrated persistent recipient B-cell mixed chimerism, whereas T-cell and granulocyte fractions showed complete donor chimerism. Given the suspected pathogenic role of residual recipient B cells, rituximab was administered as a targeted B-cell-directed therapy. This resulted in reticulocyte recovery, resolution of transfusion dependence, and conversion to complete donor B-cell chimerism.
CONCLUSION: This case suggests that recipient B-cell persistence may contribute to the pathogenesis of posttransplant PRCA and highlights the potential value of lineage-specific chimerism analysis in clarifying the underlying mechanism and guiding mechanism-based therapy, including rituximab.
METHODS: We report a pediatric case of late-onset PRCA after reduced-intensity allogeneic HSCT. Clinical course and lineage-specific chimerism analyses were retrospectively reviewed.
RESULTS: Lineage-specific chimerism analysis demonstrated persistent recipient B-cell mixed chimerism, whereas T-cell and granulocyte fractions showed complete donor chimerism. Given the suspected pathogenic role of residual recipient B cells, rituximab was administered as a targeted B-cell-directed therapy. This resulted in reticulocyte recovery, resolution of transfusion dependence, and conversion to complete donor B-cell chimerism.
CONCLUSION: This case suggests that recipient B-cell persistence may contribute to the pathogenesis of posttransplant PRCA and highlights the potential value of lineage-specific chimerism analysis in clarifying the underlying mechanism and guiding mechanism-based therapy, including rituximab.